Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris 11:35:24 2024-06-18 am EDT 5-day change 1st Jan Change
119.3 EUR -0.91% Intraday chart for Ipsen -2.85% +10.57%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Ipsen: share price soars, UBS confirms its recommendation CF
IPSEN : UBS remains Buy after FDA approval CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis CI
Ipsen: FDA grants approval for treatment CF
Ipsen Secures US FDA's Accelerated Approval for Liver Disease Drug Iqirvo MT
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment MT
Ipsen's Rare Liver Disease Treatment Gets FDA OK DJ
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug RE
US FDA approves Genfit and Ipsen's liver disease drug RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics MT
Ipsen: research partnership with Marengo extended CF
Ipsen Hires New Chief Corporate Affairs Officer MT
Ipsen: new Chief Corporate Affairs Officer CF
Ipsen: new positive data in PBC CF
Ipsen: mandate to an ISP for share buybacks CF
Ipsen: new employee shareholding operation CF
Ipsen S.A. Approves Dividend, Payable on 3 June 2024 CI
Ipsen: share price up, analyst raises target CF
IPSEN : Barclays raises its target price CF
Ipsen Announces Executive Changes CI
Ipsen: new President for North America CF
IPSEN : Better-than-expected Q1; guidance unchanged Alphavalue
Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024
Ipsen: sales up 11% in Q1 CF
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases MT
Chart Ipsen
More charts
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
119.3 EUR
Average target price
127.3 EUR
Spread / Average Target
+6.68%
Consensus
  1. Stock Market
  2. Equities
  3. IPN Stock
  4. News Ipsen
  5. France's Ipsen Extends Tender Offer To Purchase US Biopharmaceutical Epizyme